Tharimmune (THAR) announced that it has entered into subscription agreements with certain institutional and accredited investors in a private placement offering for the purchase and sale of shares of common stock at a price of $3.075 per share, for expected aggregate gross proceeds of approximately $540M, before deducting placement agent fees and other offering expenses. The closing of the Offering is expected to occur on or about November 6, 2025, subject to the satisfaction of customary closing conditions. Clear Street acted as sole placement agent and a financial advisor in connection with the Offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THAR:
- Tharimmune’s New Study on TH104: A Potential Game-Changer for PBC Treatment
- Tharimmune files to sell 327K shares of common stock for holders
- Tharimmune Increases Authorized Shares to 1 Billion
- Tharimmune Stockholders Approve Key Strategic Proposals
- Tharimmune Amends Warrants Agreement to Boost Liquidity
